FOLH1 and prostate carcinoma: Thus, we share the conclusion of Barber et al. [27] suggesting that further clinical trials are necessary to identify the optimal time point for initiation of the Lu-177-PSMA-RLT in the treatment algorithm of advanced prostate cancer.